68Ga-NOTA-RM26 PET/CT in the evaluation of glioma: a pilot prospective study
Abstract Background Gliomas are the most common malignant primary tumors of the central nervous system. There is an urgent need for new convenient, targeted and specific imaging agents for gliomas. This study aimed to firstly evaluate the feasibility of 68Ga-NOTA-RM26 PET/CT imaging in glioma and an...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-01-01
|
| Series: | EJNMMI Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13550-025-01198-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594415781150720 |
|---|---|
| author | Yilin Li Rongxi Wang Jingci Chen Zhaohui Zhu Yu Wang Wenbin Ma |
| author_facet | Yilin Li Rongxi Wang Jingci Chen Zhaohui Zhu Yu Wang Wenbin Ma |
| author_sort | Yilin Li |
| collection | DOAJ |
| description | Abstract Background Gliomas are the most common malignant primary tumors of the central nervous system. There is an urgent need for new convenient, targeted and specific imaging agents for gliomas. This study aimed to firstly evaluate the feasibility of 68Ga-NOTA-RM26 PET/CT imaging in glioma and analyze the relationship between the imaging characteristics and glioma grade, classification and molecular alterations. Results Twenty-two patients were confirmed as glioma by surgery or biopsy. All patients exhibited 68Ga-NOTA-RM26 uptake. SUVmax was chosen as the imaging marker for analysis. For all glioma patients, there were significant differences between grades (P = 0.047). For primary gliomas, SUVmax had good discrimination for both tumor classifications (P = 0.045) and grades (P = 0.03). There was a positive correlation (P < 0.01) between GRPR expression level and SUVmax. P53 mutations caused significant differences in SUVmax (P = 0.03). Conclusions This study is the first application of 68Ga-NOTA-RM26 in glioma patients and confirmed the safety and efficacy in glioma patients. 68Ga-NOTA-RM26 PET/CT has potential value in tumor grade, classification, and molecular alterations. Trial registration ClinicalTrials.gov: NCT06412952. Registered 26 April 2024, https://clinicaltrials.gov/study/NCT06412952 |
| format | Article |
| id | doaj-art-794895f26aa3445cadb1fd511a528763 |
| institution | Kabale University |
| issn | 2191-219X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | EJNMMI Research |
| spelling | doaj-art-794895f26aa3445cadb1fd511a5287632025-01-19T12:38:23ZengSpringerOpenEJNMMI Research2191-219X2025-01-0115111310.1186/s13550-025-01198-768Ga-NOTA-RM26 PET/CT in the evaluation of glioma: a pilot prospective studyYilin Li0Rongxi Wang1Jingci Chen2Zhaohui Zhu3Yu Wang4Wenbin Ma5Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeChinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAbstract Background Gliomas are the most common malignant primary tumors of the central nervous system. There is an urgent need for new convenient, targeted and specific imaging agents for gliomas. This study aimed to firstly evaluate the feasibility of 68Ga-NOTA-RM26 PET/CT imaging in glioma and analyze the relationship between the imaging characteristics and glioma grade, classification and molecular alterations. Results Twenty-two patients were confirmed as glioma by surgery or biopsy. All patients exhibited 68Ga-NOTA-RM26 uptake. SUVmax was chosen as the imaging marker for analysis. For all glioma patients, there were significant differences between grades (P = 0.047). For primary gliomas, SUVmax had good discrimination for both tumor classifications (P = 0.045) and grades (P = 0.03). There was a positive correlation (P < 0.01) between GRPR expression level and SUVmax. P53 mutations caused significant differences in SUVmax (P = 0.03). Conclusions This study is the first application of 68Ga-NOTA-RM26 in glioma patients and confirmed the safety and efficacy in glioma patients. 68Ga-NOTA-RM26 PET/CT has potential value in tumor grade, classification, and molecular alterations. Trial registration ClinicalTrials.gov: NCT06412952. Registered 26 April 2024, https://clinicaltrials.gov/study/NCT06412952https://doi.org/10.1186/s13550-025-01198-7Glioma68Ga-NOTA-RM26Gastrin-releasing peptide receptor (GRPR)PET/CT |
| spellingShingle | Yilin Li Rongxi Wang Jingci Chen Zhaohui Zhu Yu Wang Wenbin Ma 68Ga-NOTA-RM26 PET/CT in the evaluation of glioma: a pilot prospective study EJNMMI Research Glioma 68Ga-NOTA-RM26 Gastrin-releasing peptide receptor (GRPR) PET/CT |
| title | 68Ga-NOTA-RM26 PET/CT in the evaluation of glioma: a pilot prospective study |
| title_full | 68Ga-NOTA-RM26 PET/CT in the evaluation of glioma: a pilot prospective study |
| title_fullStr | 68Ga-NOTA-RM26 PET/CT in the evaluation of glioma: a pilot prospective study |
| title_full_unstemmed | 68Ga-NOTA-RM26 PET/CT in the evaluation of glioma: a pilot prospective study |
| title_short | 68Ga-NOTA-RM26 PET/CT in the evaluation of glioma: a pilot prospective study |
| title_sort | 68ga nota rm26 pet ct in the evaluation of glioma a pilot prospective study |
| topic | Glioma 68Ga-NOTA-RM26 Gastrin-releasing peptide receptor (GRPR) PET/CT |
| url | https://doi.org/10.1186/s13550-025-01198-7 |
| work_keys_str_mv | AT yilinli 68ganotarm26petctintheevaluationofgliomaapilotprospectivestudy AT rongxiwang 68ganotarm26petctintheevaluationofgliomaapilotprospectivestudy AT jingcichen 68ganotarm26petctintheevaluationofgliomaapilotprospectivestudy AT zhaohuizhu 68ganotarm26petctintheevaluationofgliomaapilotprospectivestudy AT yuwang 68ganotarm26petctintheevaluationofgliomaapilotprospectivestudy AT wenbinma 68ganotarm26petctintheevaluationofgliomaapilotprospectivestudy |